| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $156,280,220 ) (Continued on the next page) |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U24CA285296 | ISIC-REPO; ISIC Skin Imaging Repository Enhancements for Promoting Interoperability and Utilization | 000 | 2 | NIH | 3/13/2025 | $626,533 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA292178 | Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response | 000 | 1 | NIH | 2/24/2025 | $205,700 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA270018 | Deciphering the Acidic Tumor Environment: A Phase I/IIa Study of Pre-Operative Multiparametric MRI and pHLIP® ICG Intra-Operative Fluorescence Imaging of Primary Breast Cancer | 002 | 3 | NIH | 5/22/2025 | $65,164 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA270018 | Deciphering the Acidic Tumor Environment: A Phase I/IIa Study of Pre-Operative Multiparametric MRI and pHLIP® ICG Intra-Operative Fluorescence Imaging of Primary Breast Cancer | 001 | 3 | NIH | 2/28/2025 | $586,485 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA255211 | Targeting immune suppressive microenvironment in ATC | 001 | 5 | NIH | 5/22/2025 | $44,073 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA255211 | Targeting immune suppressive microenvironment in ATC | 000 | 5 | NIH | 2/14/2025 | $396,645 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01MD016908 | Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity) | 001 | 4 | NIH | 4/25/2025 | $72,522 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01MD016908 | Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity) | 000 | 4 | NIH | 2/18/2025 | $652,690 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA238317 | Lipid programs in melanocyte transformation | 001 | 6 | NIH | 5/30/2025 | $28,481 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA238317 | Lipid programs in melanocyte transformation | 000 | 6 | NIH | 3/3/2025 | $256,330 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA271287 | Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer | 001 | 4 | NIH | 4/28/2025 | $1,101,453 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA271287 | Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer | 002 | 4 | NIH | 5/28/2025 | $122,908 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F99CA294267 | Identifying and Targeting Drivers of Impaired Translation in Tumor-infiltrating CD8+ T-cells. | 000 | 1 | NIH | 1/28/2025 | $3,000 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35GM156454 | Decoding the Ubiquitin and Autophagy Signaling Networks | 000 | 1 | NIH | 1/30/2025 | $440,000 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AR068128 | Mechanisms and Function of Myonuclear Positioning | 000 | 10 | NIH | 1/28/2025 | $547,414 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA251543 | Metabolic control of normal and malignant hematopoiesis | 000 | 6 | NIH | 7/22/2025 | $964,128 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA262662 | Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases | 000 | 4 | NIH | 7/31/2025 | $693,184 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01AT012984 | The Human DNA virome: from petabase scale to single-cell resolution | 000 | 2 | NIH | 7/31/2025 | $1,023,832 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA273923 | Intensive Blood Pressure Control During Cardiotoxic Breast Cancer Treatment (PROTECT) Trial | 000 | 3 | NIH | 5/21/2025 | $580,036 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01FD008181 | Phase II trial of avutometinib plus defactinib in RAF dimer-driven thyroid cancers | 000 | 2 | FDA | 7/11/2025 | $194,528 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA286566 | A Mechanoimmunological Basis for Metastatic Site Preference | 000 | 2 | NIH | 7/31/2025 | $558,034 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA263967 | Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors | 000 | 5 | NIH | 5/8/2025 | $727,406 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA285856 | Targeting the ROR2/p-GSK3bS9 pathway to suppress metastasis in SMARCA4-deficient lung adenocarcinoma | 000 | 2 | NIH | 6/26/2025 | $544,255 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U24CA264369 | M-ISIC: A Multimodal Open-Source International Skin Imaging Collaboration Informatics Platform for Automated Skin Cancer Detection | 000 | 4 | NIH | 8/4/2025 | $808,749 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA266535 | Influence of intra-individual variability in serial screening samples on clinical decision-making for risk stratification and biopsy by a single PSA and additional markers | 001 | 4 | NIH | 7/23/2025 | $385,834 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA286469 | Understanding lung cancer genomics in patients of African ancestry | 000 | 2 | NIH | 7/1/2025 | $730,400 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37AI093808 | INITIATION OF THE IMMUNE RESPONSE TO ASPERGILLUS FUMIGATUS | 000 | 16 | NIH | 6/16/2025 | $670,541 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA270116 | Targeting plasticity in lung cancer | 001 | 3 | NIH | 6/11/2025 | $61,128 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA270116 | Targeting plasticity in lung cancer | 000 | 3 | NIH | 12/16/2024 | $550,161 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AI189793 | Chromatin architecture regulating trained immunity in antiviral NK cells | 000 | 1 | NIH | 7/23/2025 | $3,519,992 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA259177 | Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene. | 001 | 5 | NIH | 5/22/2025 | $52,119 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA259177 | Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene. | 000 | 5 | NIH | 3/19/2025 | $469,069 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258886 | Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma | 001 | 5 | NIH | 5/22/2025 | $46,574 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258886 | Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma | 000 | 5 | NIH | 3/5/2025 | $419,169 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | P01CA291697 | Lipid Metabolism as a Determinant of Ferroptosis Sensitivity in Cancer | 000 | 1 | NIH | 7/23/2025 | $2,489,032 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258622 | Ferroptosis and Cancer Cell Signaling | 001 | 4 | NIH | 5/22/2025 | $45,703 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258622 | Ferroptosis and Cancer Cell Signaling | 000 | 4 | NIH | 3/20/2025 | $411,339 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AI150999 | HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome | 000 | 5 | NIH | 2/25/2025 | $688,546 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA252048 | Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST) | 001 | 5 | NIH | 5/28/2025 | $62,218 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA252048 | Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST) | 000 | 5 | NIH | 2/19/2025 | $559,979 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00HG012203 | New approaches for leveraging single-cell data to identify disease-critical genes and gene sets | 001 | 5 | NIH | 4/29/2025 | $24,899 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00HG012203 | New approaches for leveraging single-cell data to identify disease-critical genes and gene sets | 000 | 5 | NIH | 3/6/2025 | $224,101 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA290400 | Investigating hypoxia as a determinant of malignant fates in pancreas cancer | 001 | 2 | NIH | 5/26/2025 | $69,512 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA290400 | Investigating hypoxia as a determinant of malignant fates in pancreas cancer | 000 | 2 | NIH | 3/3/2025 | $625,610 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35GM158422 | Mechanisms of Lipid Droplet Protein Targeting | 000 | 1 | NIH | 8/1/2025 | $440,000 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA299070 | Electronic Nose Technology to Predict and Assess Pathologic Response After Neoadjuvant Therapy and Recurrence for Non-Small Cell Lung Cancer | 000 | 1 | NIH | 6/16/2025 | $452,540 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA288692 | HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma | 002 | 2 | NIH | 5/22/2025 | $55,676 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA288692 | HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma | 001 | 2 | NIH | 3/17/2025 | $501,086 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA301130 | Deciphering pathogenesis and therapeutic vulnerabilities in germline RUNX1 mutated AML | 000 | 1 | NIH | 8/4/2025 | $495,715 |
|
